ImmunityBio(IBRX)

Search documents
ImmunityBio(IBRX) - 2021 Q1 - Quarterly Report
2021-05-14 20:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-37507 IMMUNITYBIO, INC. (Exact name of Registrant as specified in its Charter) Delaware 43-1979754 (State or ...
ImmunityBio(IBRX) - 2020 Q4 - Annual Report
2021-03-04 21:11
Commission file number: 001-37507 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO NANTKWEST, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organi ...
Nantkwest (NK) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
2021-01-21 01:29
| --- | --- | |-------|----------------------------------------| | | | | | | | | 39th Annual JP Morgan | | | Healthcare Conference January 13, 2021 | NantKwest, Inc. & ImmunityBio, Inc. – Presented at 39th Annual JP Morgan Healthcare Conference – January 13, 2021 1 Forward-Looking Statements This presentation contains forward-looking statements relating to the proposed transaction involving NantKwest, Inc. ("NantKwest") and ImmunityBio, Inc. ("ImmunityBio"), including financial estimates and statements as t ...
ImmunityBio(IBRX) - 2020 Q3 - Quarterly Report
2020-11-09 21:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-37507 NANTKWEST, INC. (Exact name of Registrant as specified in its Charter) Delaware 43-1979754 (State or other jurisdicti ...
ImmunityBio(IBRX) - 2020 Q2 - Quarterly Report
2020-08-07 13:01
(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q Delaware 43-1979754 (State or other jurisdiction of incorporation or organization) 3530 John Hopkins Court San Diego, California 92121 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (858) 633-0300 Securities registered pursuant ...
ImmunityBio(IBRX) - 2020 Q1 - Quarterly Report
2020-05-11 20:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-37507 NANTKWEST, INC. (Exact name of Registrant as specified in its Charter) Delaware 43-1979754 (State or other jurisdiction o ...
ImmunityBio(IBRX) - 2019 Q4 - Annual Report
2020-03-25 20:09
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-37507 NANTKWEST, INC. (Exact name of Registrant as specified in its Charter) Delaware 43-1979754 (State or other jurisdiction of inc ...
ImmunityBio(IBRX) - 2019 Q3 - Quarterly Report
2019-11-05 21:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Registrant's telephone number, including area code: (858) 633-0300 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _____ to _____ Commission file number: 001-37507 NANTKWEST, INC. (Exact Name of Registr ...
ImmunityBio(IBRX) - 2019 Q2 - Quarterly Report
2019-08-06 20:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _____ to _____ Commission file number: 001-37507 NANTKWEST, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 43-1979754 (State or other jur ...
ImmunityBio(IBRX) - 2019 Q1 - Quarterly Report
2019-05-08 20:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _____ to _____ Commission file number: 001-37507 NANTKWEST, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 43-1979754 (State or other ju ...